Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2016

View Archived Issues

Phase I/IIa study of anti-RSV Nanobody meets primary endpoint

BioMotiv, Indiana University launch Allinaire Therapeutics

Sentinel Oncology and NMI TT Pharmaservices receive grant for companion diagnostic development

Newly formed Orchard Therapeutics announces academic partnerships

ROS1 inhibitor DS-6051 well tolerated in first-in-human study

Tracon Pharmaceuticals's TRC-105 obtains E.U. orphan drug designation

Amgen reflects on accomplishments of first quarter 2016

Sage Therapeutics discloses GABA receptor modulators

Mitobridge and The Salk Institute for Biological Studies patent PPARdelta receptor agonists

Rigel Pharmaceuticals announces JAK inhibitors

Sanofi updates pipeline progress of first quarter 2016

Agilis Biotherapeutics' AGIL-AS gains orphan status in Europe

Topline results reported from phase IIb study of elsiglutide

Milestone achieved in Editas Medicine/Juno Therapeutics collaboration

Kastle Therapeutics acquires global development and commercialization rights for Kynamro

NCI grant to support phase II HCC study of RedHill's Yeliva

FDA accepts tazemetostat IND for mesothelioma

Phase III study of regorafenib in HCC meets primary endpoint

Ergomed to acquire Haemostatix

IDEAYA Biosciences closes series A financing and assembles leadership and advisory board

Affibody completes part of phase I study of ABY-035

BioTheryX enters licensing deal with Yissum Research Development

FDA grants priority review to olaratumab BLA in advanced soft tissue sarcoma

Relmada Therapeutics's d-Methadone shows antidepressant-like effects in vivo

FDA grants orphan drug designation for novel gene therapy as treatment of Fanconi anemia type A

Blueprint Medicines develops potent and selective RET inhibitors for cancer

Phase I data for Isarna Therapeutics' ISTH-0036 in glaucoma

Phase I/IIa study results for Parion Sciences' P-321 in dry eye disease